focus -WSS

focus

author：Wikipedia 2025-08-12 08:27:22 - browse：22

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Sen. Bill Cassidy on how to lower drug prices

leisure time

WSS

Sen. Bill Cassidy on how to lower drug prices

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Is there really a nursing shortage in the U.S.?

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Drinking water from half of US faucets contains PFAS: Study

Smaller biotechs seek to piggyback on weight loss drug boom

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

How AI can help patients find reliable information about doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Neutralizing antibodies against HIV shows promise in children

Novavax promises a turnaround & Lilly roils the obesity market

Is there really a nursing shortage in the U.S.?

Novavax promises a turnaround & Lilly roils the obesity market

UPS workers' union leader explains what's at stake as strike edges closer

Jerome Adams on the need for new antivirals for Covid

Health tech investors get more selective as pandemic boom fades

hotspot

Roche drug slashes death risk in early

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

How redistricting in 6 states could affect who controls Congress

CZI to create biohub to build anti

North Korean leader's powerful sister says warplanes repelled US spy plane

Another man arrested in connection with shooting at Kansas nightclub

explore

leisure time

hotspot

explore